A Phase IIIb Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

September 28, 2025

Primary Completion Date

November 10, 2026

Study Completion Date

November 10, 2026

Conditions

Diabetes

Interventions

DRUG

GZR4

GZR4 s.c., once-weekly，treat-to-target dose

DRUG

Insulin Icodec group

insulin Icodec s.c., once-weekly，treat-to-target dose

Trial Locations (1)

Gan & Lee Pharmaceuticals Shandong Co., Ltd., Linyi